Bristol-Myers extends agreement with Saladax Biomedical

The agreement is also extended to include another company – Ortho-Clinical Diagnostics.

As per the agreement, the three companies will partner to develop and to apply regulatory approvals for certain diagnostic assays.

For the commercialization of the assays, a seperate agreement is signed between Saladax and Ortho-Clinical Diagnostics.

Bristol-Myers Squibb Alzheimer disease lead and Neuroscience and Global Development vice president Jane Tiller said by pursuing the development of validated assays that could assist physicians in the diagnosis of Alzheimer’s disease, they can continue to advance the understanding and treatment of this devastating disease.

Bristol-Myers Squibb and Saladax have entered into an agreement, in May 2010, to develop clinical diagnostic tests to be used in conjunction with the development of certain therapeutic compounds in the Bristol-Myers Squibb pipeline.

Saladax has gained rights to commercialize the assays it develops.